Asa SL, Lloyd RV, Tischler AS. Neuroendocrine Neoplasms: Historical Background and Terminologies. In: Asa SL, La Rosa S, Mete O, ed.^, eds. The Spectrum of Neuroendocrine Neoplasia. Cham: Springer, 2021; 1–14.

Chapter  Google Scholar 

Rindi G, Mete O, Uccella Set al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology 33: 115–154, 2022.

Article  PubMed  Google Scholar 

Bennasroune A, Gardin A, Aunis D, Crémel G, Hubert P Tyrosine kinase receptors as attractive targets of cancer therapy. Critical Reviews in Oncology/Hematology 50: 23–38, 2004.

Article  PubMed  Google Scholar 

Qin S, Li A, Yi M, Yu S, Zhang M, Wu K Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. Journal of Hematology & Oncology 12: 27, 2019.

Article  Google Scholar 

Mosalem O, Sonbol MB, Halfdanarson TR, Starr JS Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms. Best Pract Res Clin Endocrinol Metab 37: 101796, 2023.

Article  PubMed  Google Scholar 

Donis-Keller H, Dou S, Chi Det al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2: 851–856, 1993; Mulligan LM, Kwok JB, Healey CSet al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363: 458–460, 1993; Carlson KM, Dou S, Chi Det al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 91: 1579–1583, 1994; Hofstra RM, Landsvater RM, Ceccherini Iet al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367: 375–376, 1994; Eng C, Smith DP, Mulligan LMet al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3: 237–241, 1994; Marsh DJ, Learoyd DL, Andrew SDet al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 44: 249–257, 1996.

Grieco M, Santoro M, Berlingieri MTet al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60: 557–563, 1990; Santoro M, Dathan NA, Berlingieri MTet al. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 9: 509–516, 1994; Bongarzone I, Butti MG, Coronelli Set al. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 54: 2979–2985, 1994; Minoletti F, Butti MG, Coronelli Set al. The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2. Genes Chromosomes Cancer 11: 51–57, 1994; Bongarzone I, Monzini N, Borrello MGet al. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A. Mol Cell Biol 13: 358–366, 1993; Klugbauer S, Demidchik EP, Lengfelder E, Rabes HM Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5. Cancer Res 58: 198–203, 1998.

Ribeiro TC, Latronico AC Insulin-like growth factor system on adrenocortical tumorigenesis. Mol Cell Endocrinol 351: 96–100, 2012; Livingstone C IGF2 and cancer. Endocr Relat Cancer 20: R321-339, 2013.

Fishbein L, Leshchiner I, Walter Vet al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell 31: 181–193, 2017.

Article  PubMed  PubMed Central  Google Scholar 

Salmenkivi K, Heikkilä P, Liu J, Haglund C, Arola J VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. Apmis 111: 458–464, 2003.

Article  PubMed  Google Scholar 

Yakes FM, Chen J, Tan Jet al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10: 2298–2308, 2011.

Article  PubMed  Google Scholar 

Choueiri TK, Hessel C, Halabi Set al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer 94: 115–125, 2018.

Article  PubMed  PubMed Central  Google Scholar 

Pal SK, Tangen C, Thompson IM, Jr.et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet 397: 695–703, 2021.

Article  PubMed  PubMed Central  Google Scholar 

Gherardi E, Birchmeier W, Birchmeier C, Woude GV Targeting MET in cancer: rationale and progress. Nature Reviews Cancer 12: 89–103, 2012.

Article  PubMed  Google Scholar 

Shojaei F, Lee JH, Simmons BHet al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 70: 10090–10100, 2010; Comoglio PM, Giordano S, Trusolino L Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Reviews Drug Discovery 7: 504–516, 2008.

Shibuya M Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis:A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes & Cancer 2: 1097–1105, 2011.

Article  Google Scholar 

Ferrara N, Adamis AP Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery 15: 385–403, 2016.

Article  PubMed  Google Scholar 

Grüllich C Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Recent Results Cancer Res 201: 207–214, 2014.

Article  PubMed  Google Scholar 

Taboada RG, Cavalher FP, Rego JF, Riechelmann RP Tyrosine kinase inhibitors in patients with neuroendocrine neoplasms: a systematic literature review. Ther Adv Med Oncol 16: 17588359241286751, 2024; Grillo F, Florio T, Ferraù Fet al. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. Endocrine-Related Cancer 25: R453-R466, 2018.

Grüllich C Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. Recent Results Cancer Res 211: 67–75, 2018.

Article  PubMed  Google Scholar 

Hara T, Kimura A, Miyazaki Tet al. Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor. Biochem Biophys Rep 21: 100726, 2020.

PubMed  PubMed Central  Google Scholar 

Long Z, Grandis JR, Johnson DE Emerging tyrosine kinase inhibitors for head and neck cancer. Expert Opin Emerg Drugs 27: 333–344, 2022.

Article  PubMed  PubMed Central  Google Scholar 

Fallahi P, Ferrari SM, Di Bari Fet al. Cabozantinib in Thyroid Cancer. Recent Pat Anticancer Drug Discov 10: 259–269, 2015; Wang X CBT profiles of cabozantinib approved for advanced renal cell carcinomas. Cell Biology and Toxicology 32: 259–261, 2016.

WHO. WHO. WHO Classification of Tumours, 5th Edition, Volume 10: Endocrine and Neuroendocrine Tumours https://www.iarc.who.int/news-events/publication-of-the-who-classification-of-tumours-5th-edition-volume-10-endocrine-and-neuroendocrine-tumours/. (2022). ed.^, eds. IARC. 2022.

Rindi G, Klimstra DS, Abedi-Ardekani Bet al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31: 1770–1786, 2018.

Article  PubMed  PubMed Central  Google Scholar 

Juhlin CC, Zedenius J, Höög A Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin. Endocr Pathol 31: 401–410, 2020.

Article  PubMed  PubMed Central  Google Scholar 

Lloyd RV Immunohistochemical Markers of Endocrine/Neuroendocrine Tumors. Journal of Histotechnology 22: 231–237, 1999.

Article  Google Scholar 

Cives M, Pelle E, Quaresmini D, Rizzo FM, Tucci M, Silvestris F The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Neuroendocrinology 109: 83–99, 2019.

Article  PubMed  Google Scholar 

Lauricella E, Mandriani B, Cavallo Fet al. Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications. Front Oncol 12: 957068, 2022.

Article  PubMed  PubMed Central  Google Scholar 

Bates DO Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 87: 262–271, 2010.

Article  PubMed  PubMed Central  Google Scholar 

Del Porto F, Mariotti A, Ilardi M, Messina FR, Afeltra A, Amoroso A Kidney vasculogenesis and angiogenesis: role of vascular endothelial growth factor. Eur Rev Med Pharmacol Sci 3: 149–153, 1999; Couper LL, Bryant SR, Eldrup-Jørgensen J, Bredenberg CE, Lindner V Vascular Endothelial Growth Factor Increases the Mitogenic Response to Fibroblast Growth Factor-2 in Vascular Smooth Muscle Cells In Vivo via Expression of < i > fms-</i > Like Tyrosine Kinase-1. Circulation Research 81: 932–939, 1997.

Cella CA, Cazzoli R, Fazio Net al. Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms. Endocr Relat Cancer 30, 2023.

Koenig A, Reinecke J, Halfen Jet al. Second interim analysis of CABONEN: An international, multicenter phase II trial investigating cabozantinib in patients with advanced, low proliferative NEN G3. Journal of Clinical Oncology 43: e16351-e16351, 2025.

Article  Google Scholar 

Chan JA, Geyer S, Zemla Tet al. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med 392: 653–665, 2025.

Article  PubMed  Google Scholar 

Clemente O, Starita N, Bracigliano Aet al. 1200P A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial. Annals of Oncology 34: S708, 2023.

Article  Google Scholar 

Corti F, Brizzi MP, Amoroso Vet al. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial. BMC Cancer 23: 908, 2023.

Article  PubMed  PubMed Central  Google Scholar 

Castillon JC, Molina-Cerrillo J, Viñuales MBet al. 723O Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multi-cohort basket phase II trial (CABATEN/GETNE-T1914). Annals of Oncology 34: S498, 2023.

Article  Google Scholar 

Hernando J, Molina-Cerrillo J, Grande Eet al. Cabozantinib plus atezolizumab in patients with advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II trial (CABATEN / GETNE-T1914). Journal of Clinical Oncology 42: 4128–4128, 2024.

Article  Google Scholar 

Capdevila J, Hernando J, Molina-Cerrillo Jet al. Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A multi-cohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). Clinical Cancer Research, 2025.

Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol 33: 90–114, 2022.

Article  PubMed  Google Scholar 

de Bresser CJM, de Krijger RR The Molecular Classification of Pheochromocytomas and Paragangliomas: Discovering the Genomic and Immune Landscape of Metastatic Disease. Endocrine Pathology 35: 279–292, 2024.

Article  PubMed  PubMed Central  Google Scholar 

Crona J, Taïeb D, Pacak K New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. Endocrine Reviews 38: 489–515, 2017.

Article